Published DateClear

Start Date

End Date

Category

• Business2
• Products2

Organizations

• Bausch + Lomb66
• Eyes On Eyecare51
• Alcon, Inc.46
• American Optometric Association37
• Harrow30
• Glaukos27
• Topcon Healthcare25
• Regeneron24
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• Amniotic Membrane1
• Business Management1
• Cornea1
• Finance1
• Licensing Agreement1
• Ocular Disease1
• Ocular Surface1
• Ophthalmic Tech1
• Products1
• Technology1

• Organizations: DefEYE, Inc✕

Clear all

Business

DefEYE and Celularity partner to advance ophthalmic biologics portfolios

Collaboration features a multi-million dollar investment in DefEYE as well as an exclusive sublicense of Celularity’s BIOVANCE amnion-derived ocular allografts.

Business

Verséa Ophthalmics relaunches as DefEYE Inc

Ophthalmic biologics company makes official debut with the exclusive U.S. commercial rights to the BIOVANCE franchise of decellularized biologics.

Products

Verséa Ophthalmics and Celularity partner on US distribution of two ocular products

Exclusive commercialization agreement includes Celularity’s BIOVANCE and BIOVANCE 3L Ocular products.

Products

Verséa Ophthalmics launches novel, quantitative POC testing platform for OSD

Company’s immunoglobulin (lgE) test focuses on using lgE as a biomarker for allergic conjunctivitis.